Global X Autonomous & Electric Vehicles vs Pfizer Inc — how do they compare? Global X Autonomous & Electric Vehicles trades at $36.09, while Pfizer Inc trades at $24.61 (market cap $138.21B). The key difference: Pfizer Inc pays a 7.09% dividend while Global X Autonomous & Electric Vehicles pays none, and Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| DRIV | PFE | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $28.56 |
52-Week Low | $23.67 | $23.29 |
Market Cap | — | $138.21B |
Volume | — | 29,869,932 |
Enterprise Value | — | $188.87B |
Dividend Yield | — | 7.09% |
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $35.37, down 3.2% on the day amid a bearish technical signal. The stock faces selling pressure with moving averages indicating a downtrend, though oversold RSI levels suggest potential near-term support. Recent news highlights strong global EV sales growth and China's aggressive expansion, providing a favorable industry backdrop for this electric vehicle-focused ETF.
The outlook remains cautious due to technical weakness, though industry momentum from rising EV adoption offers long-term growth potential. Key risks include regulatory uncertainty around Chinese vehicles and potential tariff impacts. Investors should monitor technical levels for stabilization signs amid volatile market conditions.
Pfizer (PFE) trades at $24.48, up 1.28% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $0.75 surpassing the $0.722 estimate. The company maintains solid profitability with a 73.51% gross margin and 11.83% net margin, while cash flow trends show positive net cash generation in 2025. News highlights focus on Pfizer's pipeline developments in obesity and oncology therapies.
The stock presents a value opportunity with a P/E of 18.51 below industry averages and a consensus price target of $28.78 implying 18% upside. However, risks include patent expirations, competitive pressures, and debt levels near 31% of assets. Analyst sentiment is mixed with 38% buy ratings versus 59% hold, suggesting cautious optimism amid pipeline execution uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →